Seres Therapeutics Inc (NASDAQ:MCRB) – Cantor Fitzgerald issued their FY2017 earnings estimates for shares of Seres Therapeutics in a research report issued to clients and investors on Tuesday, Zacks Investment Research reports. Cantor Fitzgerald analyst W. Tanner expects that the biotechnology company will post earnings of ($2.75) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock.
MCRB has been the topic of a number of other research reports. Zacks Investment Research downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 2nd. Cowen and Company restated a “buy” rating on shares of Seres Therapeutics in a report on Wednesday, February 1st. FBR & Co dropped their price objective on Seres Therapeutics from $23.00 to $18.00 and set an “outperform” rating on the stock in a report on Wednesday, February 1st. Finally, Canaccord Genuity restated a “buy” rating and issued a $20.00 price objective on shares of Seres Therapeutics in a report on Tuesday, January 31st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $23.20.
TRADEMARK VIOLATION WARNING: “Brokers Issue Forecasts for Seres Therapeutics Inc’s FY2017 Earnings (MCRB)” was published by BBNS and is the sole property of of BBNS. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://baseballnewssource.com/markets/seres-therapeutics-inc-forecasted-to-earn-fy2017-earnings-of-2-75-per-share-mcrb-updated-updated/525847.html.
Shares of Seres Therapeutics (NASDAQ:MCRB) traded down 1.87% during midday trading on Thursday, hitting $9.46. 152,632 shares of the stock were exchanged. The stock’s 50-day moving average price is $10.48 and its 200 day moving average price is $10.53. The stock’s market cap is $381.88 million. Seres Therapeutics has a one year low of $8.05 and a one year high of $35.98.
Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Thursday, March 16th. The biotechnology company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.07. The firm had revenue of $3 million for the quarter, compared to analysts’ expectations of $3 million. The company’s revenue was up NaN% compared to the same quarter last year.
Institutional investors have recently made changes to their positions in the stock. Ellington Management Group LLC bought a new position in shares of Seres Therapeutics during the fourth quarter valued at approximately $107,000. Fox Run Management L.L.C. bought a new position in shares of Seres Therapeutics during the first quarter valued at approximately $136,000. Bank of Montreal Can increased its position in shares of Seres Therapeutics by 33.7% in the first quarter. Bank of Montreal Can now owns 19,144 shares of the biotechnology company’s stock valued at $216,000 after buying an additional 4,829 shares during the period. Trexquant Investment LP increased its position in shares of Seres Therapeutics by 147.5% in the fourth quarter. Trexquant Investment LP now owns 25,924 shares of the biotechnology company’s stock valued at $257,000 after buying an additional 15,450 shares during the period. Finally, Hillhouse Capital Management Ltd. bought a new position in shares of Seres Therapeutics during the third quarter valued at approximately $259,000. Institutional investors own 77.62% of the company’s stock.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc and related companies with our FREE daily email newsletter.